<DOC>
	<DOC>NCT00972244</DOC>
	<brief_summary>The purpose of this study is to obtain information on efficacy and safety of dapagliflozin in Japanese patients with Type 2 Diabetes. This will be done by comparing the effect of dapagliflozin to placebo when given in oral doses.</brief_summary>
	<brief_title>Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Japanese Subjects with type 2 diabetes mellitus. Strictly/relatively treatment naïve Subjects with HbA1c ≥ 7.0% and ≤ 10%, or Subjects treated with single or two (less than half of the approved maximal dose for each) oral antihyperglycaemic agent with HbA1c ≤ 8%. Provision of informed consent. Having clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, retinopathy, hepatic disease and haematological disease. The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Japanese</keyword>
	<keyword>phase 2</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>dapagliflozin</keyword>
</DOC>